Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
Although osimertinib remains the preferred first-line treatment for advanced NSCLC with EGFR mutations, combining first-generation EGFR-TKIs with low-dose bevacizumab may be a viable alternative for certain patients.
Authors
- Yingqi Xu (ORCID: https://orcid.org/0000-0002-0902-2973)
- Runbo Zhong (ORCID: https://orcid.org/0000-0003-4616-1224)
- Yuqing Lou (ORCID: https://orcid.org/0000-0001-9218-2718)
- Hongping Jin (ORCID: https://orcid.org/0009-0009-9656-329X)
- Yidan Zhang (ORCID: https://orcid.org/0009-0004-0397-2873)
- Jianlin Xu
- Hua Zhong (ORCID: https://orcid.org/0000-0003-3097-5717)
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1080/07853890.2025.2493766
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04